CCDC110

Across TCGA pan-cancer cohorts, CCDC110 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CCDC110 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher CCDC110 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCDC110 expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

CESC, UCEC, and PRAD are the cancer types where CCDC110 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.068	0.830	<.001	24	view →
UCEC	DFS	Median	All	0.935	0.618	.015	10	view →
PRAD	DFS	Median	All	0.085	0.774	.009	6	view →
GBM	DFS	Median	All	1.000	0.248	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CCDC110–CESC (OS)

Open the CESC breakdown →